Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBadr University
About this trial
The goal of this clinical trial is to assess whether probiotic supplementation can improve the hematological response of CKD patients to erythropoietin therapy and prevent or reduce erythropoietin resistance. The main questions it aims to answer are:
Can probiotic be used as an adjuvant strategy in anemia management and increasing ESA responsiveness in CKD? What medical problems do participants have when taking probiotic? Researchers will compare Erythropoietin only with Erythropoietin + Probiotic to see if Probiotic aids in treating anaemic chronic kidney disease patients.
Participants will:
Take Erythropoietin + Probiotic or Probiotic only every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms
Eligibility criteria
Qualifiers
Adult patients with end stage renal disease for more than 3 months on regular hemodialysis (GFR less than 15 ml/min/m2
Receiving stable doses of erythropoietin therapy
Able and willing to provide informed consent
Disqualifiers
Recent probiotic, antibiotic, or immunosuppressive therapy
Microcytic hypochromic anemia.
Patients with hyperparathyroidism
Recent or planned kidney transplantation Gastrointestinal disorders (active IBD, cancer)
Trial design
Treatments tested in this trial
- Erythropoietin + Probiotic
- EPO
Treatment groups
80 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov